Related Experiment Video

Updated: Jul 10, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

[Management of invasive fungal infections in pediatric patient]

A Groll1

  • 1D'après la communication.

Medecine Et Maladies Infectieuses
|December 6, 2007
PubMed

Insights

Pediatric fungal infections are rising, with limited treatment options for immunocompromised children. Research is ongoing to assess the best initial therapies, including promising results for caspofungin.

Area of Science:

  • Pediatric Infectious Diseases
  • Mycology
  • Clinical Pharmacology

Background:

  • An epidemiologic shift has increased non-albicans Candida and invasive aspergillosis in children.
  • These fungal infections are a significant cause of morbidity in immunocompromised pediatric populations.
  • Current treatment options for pediatric fungal infections remain limited.

Purpose of the Study:

  • To review the current landscape of pediatric fungal infections.
  • To discuss considerations for selecting antifungal therapy in children.
  • To highlight the status of caspofungin in pediatric treatment.

Main Methods:

  • Literature review of epidemiologic shifts in pediatric mycoses.
  • Analysis of factors influencing antifungal drug selection in children.
  • Evaluation of clinical trial data and pharmacokinetic profiles for pediatric antifungal use.

Main Results:

  • Non-albicans Candida and invasive aspergillosis are increasingly prevalent in children.
  • Optimal initial antifungal treatment strategies for many pediatric infections are not yet established.
  • Caspofungin shows promising results in ongoing pediatric clinical trials, despite lacking formal approval.

Conclusions:

  • Addressing the rise in pediatric fungal infections requires careful consideration of drug choice based on clinical data, pharmacokinetics, and susceptibility.
  • Further research and clinical trials are crucial to establish effective and safe treatment guidelines for children.
  • Caspofungin represents a potential future therapeutic option for pediatric fungal infections.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...